Company / EPS (Diluted)
Corcept Therapeutics Incorporated EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$0.94
FY2025
5-year range
$0.77 / $0.94
FY2021-FY2025
Trend
+8.0%
vs FY2024
Sector context
#30 of 204
Health Care
What the data says
Corcept Therapeutics Incorporated's eps (diluted) of $0.94 is higher than 85% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-0.31 in FY2016 to $1.04 in FY2019.
Based on SEC 10-K filings.
0.94 in FY2025 with a 5-year CAGR of +9.4%. Top quartile in the Health Care sector.
Improved from $0.89 to $0.94 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +3.4%
- 5-Year CAGR
- +9.4%
- 10-Year CAGR
- -
Sector benchmark
+196.0% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 8.0% year-over-year.
- Ranks #30 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2019.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.94 | +8.0% |
| FY2024 | $0.87 | -2.2% |
| FY2023 | $0.89 | +4.7% |
| FY2022 | $0.85 | +10.4% |
| FY2021 | $0.77 | +28.3% |
| FY2020 | $0.60 | -42.3% |
| FY2019 | $1.04 | +1385.7% |
| FY2018 | $0.07 | +216.7% |
| FY2017 | -$0.06 | +80.6% |
| FY2016 | -$0.31 | +32.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026